Free Trial
NASDAQ:AIKI

AIkido Pharma (AIKI) Stock Price, News & Analysis

AIkido Pharma logo
$5.61 -0.21 (-3.61%)
As of 05/15/2025

About AIkido Pharma Stock (NASDAQ:AIKI)

Key Stats

Today's Range
$5.36
$5.87
50-Day Range
$3.37
$5.99
52-Week Range
$3.31
$11.48
Volume
304,072 shs
Average Volume
79,326 shs
Market Capitalization
$30.77 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc. in March 2021. AIkido Pharma Inc. was founded in 1967 and is headquartered in New York, New York.

Receive AIKI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AIkido Pharma and its competitors with MarketBeat's FREE daily newsletter.

AIKI Stock News Headlines

Elon just did WHAT!?
As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they gotten away with it, the Fed and U.S. banks could have seized control of our financial lives forever. But Trump stopped them cold on January 23rd, 2025, when he outlawed CBDCs… Paving the way for Elon Musk's secret master plan.
Dominari Holdings Inc trading resumes
SNOA Sonoma Pharmaceuticals, Inc.
Royalty Pharma PLC
See More Headlines

AIKI Stock Analysis - Frequently Asked Questions

AIkido Pharma's stock was trading at $0.9844 at the beginning of 2025. Since then, AIKI shares have increased by 469.9% and is now trading at $5.61.
View the best growth stocks for 2025 here
.

AIkido Pharma shares reverse split on Tuesday, June 7th 2022. The 1-17 reverse split was announced on Tuesday, June 7th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, June 7th 2022. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

AIkido Pharma subsidiaries include these companies: Hoth Therapeutics.

Shares of AIKI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that AIkido Pharma investors own include Atossa Therapeutics (ATOS), iBio (IBIO), Bionano Genomics (BNGO), Ocugen (OCGN), Meta Platforms (META), Cineverse (CNVS) and

Company Calendar

Today
5/17/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Commercial physical research
Sub-Industry
N/A
Current Symbol
NASDAQ:AIKI
Employees
4
Year Founded
1967

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-7,170,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$10,000.00
Price / Cash Flow
N/A
Book Value
$19.27 per share
Price / Book
0.29

Miscellaneous

Free Float
5,013,000
Market Cap
$30.77 million
Optionable
Not Optionable
Beta
0.93

Social Links

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:AIKI) was last updated on 5/17/2025 by MarketBeat.com Staff
From Our Partners